Literature DB >> 23917399

Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells.

Yan Xu1, Dan Wang, Li-Mei Zhao, Xi-Long Zhao, Jun-Jie Shen, Yao Xie, Li-Li Cao, Zhen-Bo Chen, Yan-Mei Luo, Bi-Hui Bao, Zhi-Qing Liang.   

Abstract

Endoglin (CD105, END) is upregulated in proliferating endothelial cells, suggesting potential therapeutic properties. However, it is not clear whether endoglin mediates an enhanced proliferative rate or may be upregulated as part of a negative feedback loop. To gain insights into context-dependent and cell type-dependent regulatory effects of endoglin, we studied its role properties in human ovarian carcinoma-derived endothelial cells (ODMECs). We isolated and cultured primary ODMECs from epithelial ovarian carcinoma tissue. ODMECs had higher expression of endoglin and VEGFR-2, and also exhibited enhanced spontaneous formation of vessel-like structures in vitro. Transfection of siRNA targeting endoglin in ODMECs cells resulted in the reduction of the proliferation and tube formation. These results indicate that a subset of ODMECs display abnormal angiogenic properties and this phenotype was blocked by decreasing endoglin levels, suggesting endoglin is essential for stimulating angiogenesis, and targeting it may be an attractive approach to anti-angiogenesis therapy for ovarian carcinoma.

Entities:  

Keywords:  ODMEC; endoglin; endothelial cells; ovarian carcinoma; siRNA

Mesh:

Substances:

Year:  2013        PMID: 23917399      PMCID: PMC3926891          DOI: 10.4161/cbt.25940

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  54 in total

Review 1.  In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents.

Authors:  Anne M Goodwin
Journal:  Microvasc Res       Date:  2007-06-06       Impact factor: 3.514

Review 2.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

3.  Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Authors:  Angela J Ziebarth; Somaira Nowsheen; Adam D Steg; Monjri M Shah; Ashwini A Katre; Zachary C Dobbin; Hee-Dong Han; Gabriel Lopez-Berestein; Anil K Sood; Michael Conner; Eddy S Yang; Charles N Landen
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

4.  Endoglin (CD105) is not a specific selection marker for endothelial cells in human islets of Langerhans.

Authors:  C P D Wheeler-Jones; C E Clarkin; C E Farrar; P Dhadda; P Chagastelles; N Nardi; P M Jones
Journal:  Diabetologia       Date:  2012-10-28       Impact factor: 10.122

5.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

Review 6.  Roles for the type III TGF-beta receptor in human cancer.

Authors:  Catherine E Gatza; Sun Young Oh; Gerard C Blobe
Journal:  Cell Signal       Date:  2010-02-12       Impact factor: 4.315

7.  Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction.

Authors:  Franck Lebrin; Marie-José Goumans; Leon Jonker; Rita L C Carvalho; Gudrun Valdimarsdottir; Midory Thorikay; Christine Mummery; Helen M Arthur; Peter ten Dijke
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

Review 8.  The emerging role of TGF-beta superfamily coreceptors in cancer.

Authors:  Carmelo Bernabeu; Jose M Lopez-Novoa; Miguel Quintanilla
Journal:  Biochim Biophys Acta       Date:  2009-07-14

9.  Cryopreservation and lentiviral-mediated genetic modification of human primary cultured corneal endothelial cells.

Authors:  Leejee H Suh; Cheng Zhang; Roy S Chuck; Walter J Stark; Stuart Naylor; Katie Binley; Shukti Chakravarti; Albert S Jun
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

10.  Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.

Authors:  Darren W Davis; Keiji Inoue; Colin P N Dinney; Daniel J Hicklin; James L Abbruzzese; David J McConkey
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

View more
  6 in total

1.  Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.

Authors:  Xiaomei Yang; Jing Zhao; Siliang Duan; Xiaoqiong Hou; Xi Li; Zixi Hu; Zhuoran Tang; Fengzhen Mo; Xiaoling Lu
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

2.  Endoglin Modulates TGFβR2 Induced VEGF and Proinflammatory Cytokine Axis Mediated Angiogenesis in Prolonged DEHP-Exposed Breast Cancer Cells.

Authors:  Mahendra Jadhao; Chun-Lin Chen; Wangta Liu; Dhanashri Deshmukh; Wei-Ting Liao; Jeff Yi-Fu Chen; Ritesh Urade; Eing-Mei Tsai; Sheng-Kai Hsu; Li-Fang Wang; Chien-Chih Chiu
Journal:  Biomedicines       Date:  2022-02-10

3.  PS1 FAD mutants decrease ephrinB2-regulated angiogenic functions, ischemia-induced brain neovascularization and neuronal survival.

Authors:  YoneJung Yoon; Georgios Voloudakis; Nathan Doran; Emily Zhang; Christina Dimovasili; Lei Chen; Zhiping Shao; Spyros Darmanis; Cheuk Tang; Jun Tang; Victoria X Wang; Patrick R Hof; Nikolaos K Robakis; Anastasios Georgakopoulos
Journal:  Mol Psychiatry       Date:  2020-06-15       Impact factor: 13.437

4.  Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.

Authors:  Brittany Anne Davidson; Jennifer M Rubatt; David L Corcoran; Deanna K Teoh; Marcus Q Bernardini; Lisa A Grace; William John Soper; Andrew Berchuck; Sharareh Siamakpour-Reihani; Wei Chen; Kouros Owzar; Susan K Murphy; Angeles Alvarez Secord
Journal:  Front Oncol       Date:  2014-06-20       Impact factor: 6.244

5.  RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.

Authors:  Dan Wang; Yan Xu; Lu Feng; Pin Yin; Shuang Shuang Song; Feng Wu; Ping Yan; Zhiqing Liang
Journal:  Oncol Rep       Date:  2018-10-22       Impact factor: 3.906

Review 6.  Endoglin in the Spotlight to Treat Cancer.

Authors:  Teresa González Muñoz; Ana Teresa Amaral; Pilar Puerto-Camacho; Héctor Peinado; Enrique de Álava
Journal:  Int J Mol Sci       Date:  2021-03-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.